Overview

A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of iguratimod compared to placebo in patients with active primary Sjogren's Syndrome.

Phase:

Phase 2

Details

Lead Sponsor:

Jiangsu Simcere Pharmaceutical Co., Ltd.